Find a Clinical Trial

Showing 1 - 10 of 33 Trials

A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer

Principal Investigator:

Jason D. Wright, MD

Contact Number:

212-342-5162

NCT Number:

NCT04633239

Population:

Adult

Phase:

I

This study is being done to answer the following question: Can abemaciclib and olaparib be taken safely together in ovarian cancer that has come back? We are asking you to take part in this research study because you have ovarian cancer that has come back. We are trying to determine whether abemaciclib and olaparib can be taken safely and tolerably together in ovarian cancer that has come back. Are you Eligible? (Inclusion Criteria) Must have ovarian cancer that has come back within 6 months of last dose of treatment. Must have received 1-3 prior treatment regimens. Must have lesions seen on...
LANCE: Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy

Principal Investigator:

Jason D. Wright, MD

Contact Number:

212-342-5162

NCT Number:

NCT04575935

Population:

Adult

Phase:

III

The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Ccancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the disease from returning for longer and/or improve your quality of life after surgery. It is considered investigational to compare the outcomes of these methods when used to treat advanced EOC in women who have responded to neoadjuvant chemotherapy. Are you Eligible? (...
SL03-OHD-105: An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05483933

Population:

Adult

Phase:

I

The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-172154 is an immunotherapy drug. Immunotherapies are treatments that use your body’s own immune (defense) system to help fight cancer. SL-172154 binds to a protein called CD47 on cancer cells and to a protein called CD40 on immune...
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT03564340

Population:

Adult

Phase:

I/II

The main purpose of this study is to: • Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. • The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. • The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer. Are you Eligible? (Inclusion Criteria) Do you have ovarian cancer? Are...
ALKS 4230-007/GOG-3063/ENGOT-ov68: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05092360

Population:

Adult

Phase:

III

The purpose of this study is to find answers to the following research questions: • How effective is nemvaleukin alone and in combination with Pembrolizumab in treating your epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with chemotherapy? • What effect does nemvaleukin alone and in combination with Pembrolizumab have on your body and epithelial ovarian, fallopian tube, or primary peritoneal cancer? • What effect does nemvaleukin in combination with Pembrolizumab have on your overall health and well-being? • How does nemvaleukin in combination...
ZN-c3-005_GOG 3066-DENALI: A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN‑c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05128825

Population:

Adult

Phase:

II

Participants are being invited to take part in a clinical research study because they have been diagnosed with locally advanced or metastatic solid tumors with mutations in the following genes: MRE11, RAD50, NBN or CCNE1 amplification. If the participant takes part in the study, they will take an investigational drug referred to as ZN-c3 (“Study Drug”). ‘Investigational’ means that the Study Drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. The purpose...
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT04300556

Population:

Adult

Phase:

I/II

The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness. This study will enroll patients with triple-negative breast cancer (TNBC), endometrial cancer (EC), non-small cell lung cancer (NSCLC, adenocarcinoma), and ovarian cancer. If it is determined that you meet all of the study entry requirements, you will get an...
AGCT1532: Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT02582697

Population:

Pediatrics/Adult

Phase:

III

This is a study for patients between 11 years and 45 years who have newly diagnosed intermediate or poor-risk metastatic germ cell tumors (GCTs). This study is looking at whether giving treatment with Bleomycin, Etoposide, and Cisplatin (BEP)every 2 weeks (accelerated BEP) or every 3 weeks (standard BEP) is better. Participants will be randomized to either Arm A: standard BEP or Arm B: accelerated BEP. All participants will receive a medication to stimulate the body to make white blood cells which has allowed some chemotherapy regimens to be given with a shorter than usual cycle length, while...
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Cemiplimab in Patients with Advanced Cancers

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT05259696

Population:

Adult

Phase:

I/II

The purpose of this study is to test the safety of the study drug, E-602, at different dose levels both alone (monotherapy) and in combination with pembrolizumab (also known as Keytruda®).Pembrolizumab is FDA-approved for the treatment of some cancers, but not all of the cancers in this study. E-602 has not been approved by the United States Food and Drug Administration (FDA). This study is the first time that E-602 will be administered to participants. The study will also inform on what effects, both good and bad, E-602 alone and in combination with pembrolizumab have on participants...
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors

Principal Investigator:

Benjamin Izar, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05098132

Population:

Adult

Phase:

I

The main purpose of this study is to determine the highest dose of STK-012 that can be given safely alone and in combination with a standard dose of pembrolizumab in subjects with advanced solid tumors, this will be assessed in the dose escalation phase of the study. In the dose expansion phase of the study, the highest dose of STK-012 that can be safely given in combination with pembrolizumab, as determined in the dose escalation phase, will be given to more people for further study.STK-012 is a modified (changed in the laboratory) form of a cytokine (protein) called interleukin-2 (IL-2)...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages